On 14 November 2019, the US Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Efficacy was evaluated in BGB-3111-206 (NCT03206970), a phase II open-label, multicentre, single-arm trial of 86 patients with MCL who received at least one prior therapy. Jun 02, 2011 · 2011-06-02T00:00:00-07:00 2011-06-02T00:00:00-07:00 FR-2011-06-02-ReaderAids Reader Aids https://regulations.justia.com/regulations/fedreg/2011/06/02/2011-13825.html
"The Accelerated Approval regulations were first instituted by the FDA in 1992 in order to speed the availability of new drugs to treat HIV/AIDS. The designation has also been frequently applied to cancer drugs and legislation passed in 2012 included a provision to expand its use to other conditions.""The FDA approval of this Tecentriq combination is an important treatment advance for people with PD-L1-positive, metastatic triple-negative breast cancer, a disease with high unmet medical need," said Sandra Horning, MD, Roche's Chief Medical Officer and Head of Global Product Development.
Oct 21, 2016 · In addition to receiving accelerated approval, the FDA granted Eli Lilly fast track designation, breakthrough therapy, priority review status and orphan drug designation for Lartruvo. Eli Lilly is currently conducting a larger clinical trial to assess the drug’s efficacy across more subtypes of soft tissue carcinoma. Over time there has been a clear tendency for FDA regulations and requirements to expand and multiply. In 1980, the typical drug underwent thirty clinical trials involving about fifteen hundred patients. By the mid-1990s, the typical drug had to undergo more than sixty clinical trials involving nearly five thousand patients.